media – Page 647 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

One in three RA patients rejecting meds because of cost

One in three people with rheumatoid arthritis in England are not taking their medicine as prescribed because of cost, according to The National Rheumatoid Arthritis Society (NRAS).
- Source: pharmatimes
- 532
- May 14, 2017
Market Views NRAS PPC
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 593
- May 10, 2017
cancer clinic Company Insight FDA gentic
Second US approval for Merck, Pfizer’s Bavencio

Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
- Source: pharmatimes
- 581
- May 10, 2017
antibody Bavencio cancer New Approvals
Ddu is ready for the United O2O Exhibitions

Drugdu Technology Co., Ltd., a developer of the leading global pharmaceutical and medical device B2B platform Drugdu.com (Ddu), today announced that it will attend Hospitalar 2017 from May 16 to 19 in Sao Paulo, Brazil. Drugdu.com will showcase products of premium members and deliver innovative solutions, which are attractive not only for its users, but for the whole healthcare industry.
- Source: Ddu
- 649
- May 9, 2017
Exhibitions & Activities Hospitalar medical device sourcing request
GSK’s inhaler improves asthma control in ‘real world’ study

GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
- Source: pharmatimes
- 579
- May 8, 2017
asthma Company Insight therapy
WHO improves transparency of financial data

WHO is improving transparency and accountability with the launch of a redesigned Programme Budget Web Portal that makes budget and spending information easier to access, use and understand.
- Source: pharmatimes
- 565
- May 4, 2017
IATI Market Views WHO
NICE nods for Amgen’s rare leukaemia drug

Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
- Source: pharmatimes
- 640
- May 3, 2017
cancer Company Insight NHS NICE therapy
The First Communication Meeting with Ddu High Priority Members

Recently, The first face-to-face communication meeting with Ddu high priority members was held by Drugdu.com (Ddu), a global leading pharmaceutical and medical device B2B Online platform. Ddu and the members together discussed the future trend of medical cross-border trade, introduced credit guarantee system, exhibition promotion service and development plan. Ddu also answered questions from members.
- Source: Ddu
- 880
- April 22, 2017
credit verification Exhibitions & Activities member promotion
Ddu Global Promotion Plan — KIMES

The 33rd Korea International Medical& Hospital Equipment Show(KIMES 2017) took place from March 16th to 19th for four days at COEX in Seoul. As an exhibitor, Ddu introduced a special B2B experience to international companies of pharmaceutical and medical device, which won high praise from partners and visitors at home and abroad.
- Source: DDu
- 730
- March 20, 2017
Exhibitions & Activities KIMES promotion

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.